Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-miR-449b
- Development stage
- Preclinical
- Lead developer
- The Chinese University of Hong Kong
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
anti-miR-449b is a microRNA inhibitor (antagomir or antisense oligonucleotide) designed to target and sequester mature miR-449b. In research concerning endometrial cancer, miR-449b has been identified as a significantly upregulated microRNA in advanced-stage tumors compared to early-stage or normal tissue. By binding to miR-449b, this agent prevents the microRNA from downregulating its natural tumor-suppressive targets, thereby inhibiting the migration and invasion of cancer cells. Studies presented at the AACR have highlighted anti-miR-449b as a potential therapeutic candidate for endometrioid endometrial adenocarcinoma (EEC).
- Other names
- miR-449b inhibitormiR449b inhibitormiR 449b inhibitorantagomir-449bantagomir449bantagomir 449banti-microRNA-449banti-microRNA449banti-microRNA 449b
Beyond the preview
Go deeper on anti-miR-449b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-miR-449b.